EP3536712
METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
Zusammenfassung
[0001] The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
Anmelder
REGENERON PHARMA [US]
Erfinder
SWERGOLD GARY [US]
Externe Quellen
Klassifikation
IPC-Klassen
A61P 3/06C07K 16/40A61K 39/00A61P 11/00A61P 27/02A61P 43/00A61P 7/00A61P 9/00A61P 9/10
CPC-Klassen
A61K 39/3955A61P 11/00A61P 27/02A61P 3/06A61P 43/00A61P 7/00A61P 9/00A61P 9/10C07K 16/40
AI: Life Sciences
warum
Regeneron PCSK9 antibody (parallel filing) — A61K39 + A61P9/10 + C07K16/40. Pure pharma.